<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161199</url>
  </required_header>
  <id_info>
    <org_study_id>H52899-34904-01</org_study_id>
    <nct_id>NCT01161199</nct_id>
  </id_info>
  <brief_title>The Use of Leukapheresis to Support HIV Pathogenesis Studies</brief_title>
  <official_title>The Use of Leukapheresis to Support HIV Pathogenesis Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the dramatic improvements that have resulted from combination antiretroviral
      treatment, long-term efficacy, toxicity, cost, and the requirements for life-long adherence
      remain as formidable challenges. Also, there is emerging consensus that persistent
      HIV-associated disease occurs during long-term highly active antiretroviral therapy (HAART).
      This disease may be due to either direct drug-toxicity and/or persistent viral
      replication/production and/or persistent HIV-associated inflammation. Hence, strategies aimed
      at achieving complete viral eradication may be needed in order to fully restore health among
      HIV infected individuals. Even if complete eradication proves impossible—as most believe to
      be the case—a less rigorous but still desirable outcome might be achieving durable control of
      virus in the absence of therapy. That a &quot;functional&quot; cure is possible is well illustrated by
      those rare individuals who are able to durably control replication competent virus in the
      absence of therapy (&quot;elite&quot; controllers).

      A more complete understanding of the relationship between inflammation and viral persistence
      is necessary before more rationale studies of HIV eradication can be designed. Also, a well
      validated high through-put virologic assay needs to be developed that can estimate the size
      of the latent reservoir. Since the level of replication competent virus in long-term treated
      patients (and in elite controllers) is very small (&lt; 1% of CD4 cells harbor HIV), large
      numbers of CD4+ T cells most be obtained from study participants in order to routinely
      isolate and quantify virus persistence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV DNA and RNA</measure>
    <time_frame>Baseline and 6-12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Untreated non-controllers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Elite controllers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HAART-suppressed</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.</description>
    <arm_group_label>Untreated non-controllers</arm_group_label>
    <arm_group_label>Elite controllers</arm_group_label>
    <arm_group_label>HAART-suppressed</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CD4+ T cells Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients on long-term antiretroviral therapy, untreated patients, and elite
        controllers will be studied.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV seropositive

          -  Able to give informed consent

          -  Willing to undergo blood sampling and/or leukapheresis

          -  Meeting one of the following criteria: (1) on stable highly active antiretroviral
             therapy (HAART) with a recent undetectable viral load (&lt; 50 copies/mL) (&quot;HAART
             suppressed&quot;), (2) antiretroviral untreated with an undetectable viral load (&lt; 50
             copies/mL) (&quot;elite&quot; controllers) and (3) antiretroviral untreated with a detectable
             viral load (&gt; 1000 copies/mL) (&quot;non-controllers&quot;)

        Exclusion Criteria:

          -  Known anemia (HIV+ males Hct&lt;34; females Hct&lt;32) or contraindication to donating blood

          -  Blood coagulation disorder (including bleeding tendency or problems in past with blood
             clots)

          -  Platelets &lt; 50,000/mm3

          -  PTT &gt; 2x ULN

          -  INR &gt; 1.5

          -  Albumin &lt; 2.0 g/dL

          -  ALT &gt; 5x ULN

          -  AST &gt; 5x ULN

          -  Biopsy-proven or clinical diagnosis of cirrhosis

          -  Weight &lt;120 lb

          -  High blood pressure &gt; 160/100

          -  Low blood pressure &lt; 100/70

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroyu Hatano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroyu Hatano, MD</last_name>
    <phone>415-476-4082</phone>
    <phone_ext>122</phone_ext>
    <email>hhatano@php.ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven G. Deeks, MD</last_name>
    <phone>415-476-4082</phone>
    <phone_ext>404</phone_ext>
    <email>sdeeks@php.ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyu Hatano, MD</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>122</phone_ext>
      <email>hhatano@php.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Steven G. Deeks, MD</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>404</phone_ext>
      <email>sdeeks@php.ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hiroyu Hatano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>latent reservoir</keyword>
  <keyword>functional cure</keyword>
  <keyword>leukapheresis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

